Professional Documents
Culture Documents
Antimicrobial Surface Functionalization of Plastic Catheters by Silver Nanoparticles
Antimicrobial Surface Functionalization of Plastic Catheters by Silver Nanoparticles
Antimicrobial Surface Functionalization of Plastic Catheters by Silver Nanoparticles
doi:10.1093/jac/dkn034
Advance Access publication 27 February 2008
David Roe1, Balu Karandikar1, Nathan Bonn-Savage1, Bruce Gibbins1 and Jean-Baptiste Roullet2*
1
AcryMed, Inc., 9560 SW Nimbus Avenue, Beaverton, OR 97008, USA; 2Oregon Health & Science University,
707 SW Gaines Road, Portland, OR 97221, USA
Received 13 April 2007; returned 19 August 2007; revised 2 January 2008; accepted 11 January 2008
Introduction also increase the risk of infection, accounting for 80% of all
nosocomial urinary tract infections.6
More than 200 000 nosocomial bloodstream infections occur The insertion of catheters under sterile conditions is the most
each year in the USA and most of them are related to the use of effective measure to prevent catheter-associated infective com-
intravascular devices.1,2 Central venous catheters are a particu- plications.7 Despite concerns that they would lead to compla-
larly high risk category of devices.3,4 According to recent esti- cency regarding septic techniques, catheters with antimicrobial
mates, the use of 1 in 20 of the 7 million central venous properties have nonetheless been proposed as a means to
catheters inserted annually is associated with catheter-related provide additional protection and further reduce the risk of
bloodstream infection.2,5 Chronic indwelling urinary catheters infection.8,9 A number of such devices have been developed10 –
.....................................................................................................................................................................................................................................................................................................................................................................................................................................
869
# The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University
Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its
entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Roe et al.
12
and tested with variable success in clinical studies.4,6 Biofilm formation inhibition assay and bactericidal activity
However, the ideal catheter, a catheter that combines low-cost measurements
coating technology, wide-spectrum and long-lasting antimicro-
bial properties, and safe utilization, has yet to be developed. Silver-coated catheters (650 mg silver/g) were placed in tubes (8
1 cm strips/tube) containing growth medium (1 mL/tube; 1% bovine
The objective of the studies presented in this report was to
serum albumin, 0.1% neopeptone, 0.25% glucose) and 103 test
develop a new method to deposit silver nanoparticles at low
microorganisms (test tubes). Six different microorganisms (clinical
temperature on plastic catheters, determine the antimicrobial
strains) were tested: (i) Escherichia coli; (ii) Enterococcus;
activity of these catheters in vitro and examine their silver- (iii) Staphylococcus aureus; (iv) Pseudomonas aeruginosa;
releasing properties both in vitro and in vivo. The data suggest (v) coagulase-negative staphylococci; and (vi) Candida albicans.
that plastic catheters coated with silver nanoparticles may be Tubes containing non-coated catheters and tubes containing growth
effective in reducing the infectious risk associated with chronic medium but no catheter and no microorganism (controls) were pre-
catheterization in humans. pared in parallel. The tubes were then incubated for either 24, 48 or
72 h at 358C. A count of free floating viable bacteria and the deter-
mination of viable sessile bacteria by means of a biofilm formation
Materials and methods assay were performed at each time point. Biofilm formation was
estimated using the tetrazolium salt XTT assay as previously
Materials and reagents described.13,14 Results were expressed in per cent inhibition of
870
Silver nanotechnology and antimicrobial catheters
871
Roe et al.
Pathogen 24 h 48 h 72 h
E. coli
biofilm 88 + 3.3 95 + 1 83 + 3
growth 100 100 100
Enterococcus
biofilm 16 + 7 32 + 5 66 + 4
growth 100 100 100
S. aureus
biofilm 93 + 2 95 + 1 78 + 4
growth 100 100 100
Coagulase-negative staphylococci
biofilm 39 + 17 86 + 11 50 + 16
growth 100 100 100
P. aeruginosa
872
Silver nanotechnology and antimicrobial catheters
110m
Figure 4. Silver urine (open circles) and faeces (filled circles) excretion in mice implanted with Ag-coated catheters. (a) Daily excretion. (b) Cumulative
Table 2. Biodistribution of silver (mg per sample and % of Silver has long been known for its broad antimicrobial prop-
implanted silver) on day 10 (mean + SEM; n ¼ 7) erties. These properties are believed to result from the disruption
of the energy metabolism and electrolyte transport systems,
Percentage of which occurs when silver ions bind to bacterial sulphydryl- or
Silver (mg) implanted silver histidyl-containing proteins.17 The use of silver to reduce the
risk of catheter-related infection was proposed 20 years ago by
Catheters (initial) 221.7 + 0.8 — Maki et al.,18 who tested the efficacy of a biodegradable col-
Catheters on day 10 186.2 + 2.6 83.9 lagen matrix impregnated with bactericidal silver. Since then, a
Implantation site (skin, 6.8 + 0.4 3.1 number of other methods have been developed to create cath-
panniculus carnosus, scar eters capable of delivering silver.19 These methods include elec-
tissue) tron beam assisted deposition,20,21 distribution of submicron
Rib cage þ muscle underlying 0.4 + 0.1 0.2 particles of metallic silver in the polyurethane matrix of the
the implantation site catheter,17 placement of silver wires at the cutaneous extremity
All other tissues and organs: 0.1% of implanted silver or no of the catheters and release of silver by iontophoresis,22,23 and
detectable silver catheter impregnation with silver nanoparticles using supercriti-
Urine (cumulative 10 days) 0.22 + 0.04 0.1 cal carbon dioxide.24 These methods are all relatively complex
Faeces (cumulative 10 days) 18.33 + 0.99 8.3 and expensive.
Recovery 95.6 To come up with a simpler and cheaper coating method,
silver nanoparticle production technologies were reviewed. None
Urine and faeces data are from Figure 4. of them seemed to provide a rate of nanoparticle formation and
deposition that was fast enough to be compatible with the logis-
tic of efficient industrial production. Further, many of them
utilize either starting silver salt concentrations too low (10 mM
The 4% unaccounted for are likely to be found at the implan-
or less) to yield potentially antimicrobial concentrations at the
tation site on the borders of the insertion pocket associated with
surface of the catheters or agents that are toxic or at least not
either serous liquid or scar tissue.
biocompatible, thus precluding the use of silver nanoparticles
made by these methods because of toxicity concerns.25,26 The
method described in this report is simple, uses non-toxic
Discussion chemicals and yields reproducible coating of plastic catheters
with typical nanoparticles of silver as confirmed by electron
This report describes a method to prepare catheters coated with microscopy. The amount of silver deposited is proportional to
silver nanoparticles and presents evidence for the catheters’ anti- the concentration of silver nitrate used in the coating solution
microbial properties and safety of use in animals. The method (Figure 1), at least within the range tested and thus can be
uses silver nitrate and a mix of low-toxicity coating inducers. reasonably predicted. Importantly, coating takes place on both
The coating process is slowly reversible, yielding sustained the luminal and the external surface of the catheters, thus pro-
release of silver for at least 10 days. The released silver is active viding a double protection against microorganism penetration at
against microorganisms most commonly found responsible for the implantation site. Further, the coating method does not affect
nosocomial infections and predominantly accumulates at the site the size or the diameter of the catheters (Figure 2d) and is resist-
of insertion, thus suggesting that catheters coated with this ant to handling. Thus, this method preserves the original qual-
method could provide enhanced local protection against infec- ities of manufactured catheters and will likely not affect their
tions with no risk of systemic toxicity. handling during clinical use.
873
Roe et al.
The size distribution of the nanoparticles is relatively broad the lumen of the catheters. More extensive microscopic analysis
(3 –18 nm) but actually quite tight considering the simplicity of of the catheters after coating and at different times during
the production process. Whether or not the distribution impacts elution may be useful in the future to test these hypotheses.
the microbicidal activity of the catheters is not known at this Bacterial resistance to silver has been a concern with the sig-
point. One could speculate that for a given amount of coated nificant increase in the usage of silver-containing products to
silver, smaller particles will yield a greater contact surface with manage infections.28,29 Several studies suggest that it is second-
the liquid environment and will be more active than larger par- ary to a plasmid-related increase in silver binding to periplasmic
ticles. Alternatively, larger particles may provide a slower but membrane proteins and in silver efflux through two
more prolonged release of silver, a benefit for catheters destined plasmid-encoded pumps.27,30 The potential benefits of wide-
for longer-term implantation. The issue of size – activity relation- spread usage of silver-nanoparticle coated catheters may thus be
ship is thus important to consider and will be the focus of future in part offset by the emergence of new, silver-resistant bacterial
studies. strains. Such possibility exists with any new antimicrobial agent
The overwhelming majority of nosocomial infections but is perhaps less to fear with silver than with other agents. As
associated with catheter use are caused by coagulase-negative pointed out by Chopra29, target-based mutation to silver resist-
staphylococci such as Staphylococcus epidermidis.1,4,7 ance is unlikely because of the multiplicity of intracellular
Infections caused by S. aureus, Enterococcus and E. coli are targets of silver ions and may explain in part the limited number
also frequent and are often associated with increased resistance of reports of silver resistance in bacteria published so far.
874
Silver nanotechnology and antimicrobial catheters
875
Roe et al.
21. Trerotola SO, Johnson MS, Shah H et al. Tunneled hemodialy- 29. Chopra I. The increasing use of silver-based products as antimi-
sis catheters: use of a catheter for prevention of infection—a random- crobial agents: a useful development or a cause of concern?
ized study. Radiology 1998; 207: 491–6. J Antimicrob Chemother 2007; 59: 587–90.
22. Raad I, Hachem R, Zermeno A et al. In vitro antimicrobial effi- 30. Silver S. Bacterial silver resistance: molecular biology and uses
cacy of silver iontophoretic catheter. Biomaterials 1996; 17: 1055–9. and misuses of silver compounds. FEMS Microbiol Rev 2003; 27:
23. Raad I, Hachem R, Zermeno A et al. Silver iontophoretic cath- 341–53.
eter: a prototype of a long-term antiinfective vascular access device. 31. Armitage SA, White MA, Wilson HK. The determination of silver
J Infect Dis 1996; 173: 495 –8. in whole blood and its application to biological monitoring of
24. Furno F, Morley KS, Wong B et al. Silver nanoparticles and poly- occupationally exposed groups. Am Occup Hyg 1996; 40:
meric medical devices: a new approach to prevention of infection? 331–8.
J Antimicrob Chemother 2004; 54: 1019– 24. 32. Saber H, Anner RM, Anner BM. Cysteine protects Naþ/
25. Nickel U, Castell AZ, Poppl K et al. A silver colloid produced by þ
K -ATPase and isolated human lymphocytes from silver toxicity.
reduction with hydrazine as support for highly sensitive Biochem Biophys Res Commun 1992; 189: 1444–9.
surface-enhanced Raman spectroscopy. Langmuir 2000; 16: 9087–91. 33. Wright JB, Lam K, Buret AG et al. Early healing events in a
26. Green M, Allsop N, Wakefield G et al. Trialkylphosphine oxide/ porcine model of contaminated wounds: effects of nanocrystalline
amine stabilized silver nanocrystals—the importance of steric factors silver on matrix metalloproteinases, cell apoptosis, and healing. Wound
and Lewis basicity in capping agents. J Mater Chem 2002; 12: Rep Reg 2002; 10: 141–51.
2671–4.
34. Furchner JE, Richmond CR, Drake GA. Retention of silver-110m
876